Overview

Efficacy Study of Sodium Channel Blocker in LQT3 Patients

Status:
Completed
Trial end date:
2018-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborator:
Gilead Sciences
Treatments:
Ranolazine
Sodium Channel Blockers